臨床検査55巻12号

2011年11月発行

今月の主題 子宮頸癌の予防と検査 各論 〈検査手技・判定の実際〉

ヒトパピローマウイルス(HPV)DNA検査―Hybrid Capture^®法，PCR法の特徴

著者： 笹川寿之¹

所属機関： ¹金沢医科大学産科婦人科

ページ範囲：P.1433 - P.1443

HPV-DNA検査は大きくhybridization法と遺伝子増幅法とに分けられる．13タイプの高リスク型HPV(HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68型)を一括して検出する検査法として，hybridization法をベースにした第2世代Hybrid Capture^®2(HC-2)法とPCR法をベースにしたアンプリコア^®HPV検査がある．HPV型を判定するHPV genotyping法には遺伝子増幅法のPCR法とLAMP法が用いられている．HPV検査は，使用目的とその限界をよく理解したうえで用いるべきである．

参考文献

1) Bernard HU, Burk RD, Chen Z, et al : Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology　401：70-79，2010

2) Matsukura T, Sugase M : Human papillomavirus genomes in squamous cell carcinomas of the uterine cervix. Virology　324：439-449，2004(Erratum in Virology　331：204-205，2005)

3) Sasagawa T, Basha W, Yamazaki H, et al : High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol Biomarkers Prev　10：45-52，2001

4) de Sanjose S, Quint WG, Alemany L, et al : Human papillomavirus genotype attribution in invasive cervical cancer : a retrospective cross-sectional worldwide study. Lancet Oncol　11：1048-1056，2010

5) Rahman M, Sasagawa T, Yamada R, et al : High Prevalence of Intermediate-Risk Human Papillomavirus Infection in Uterine Cervices of Kenyan Women Infected with Human Immunodeficiency Virus. J Med Virol in press

6) Notomi T, Okayama H, Masubuchi H, et al : Loop-mediated isothermal amplification of DNA. Nucleic Acids Res　28：E63，2000

7) Wentzensen N, Gravitt PE, Solomon D, et al : A study of Amplicor human papillomavirus DNA detection in the atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study. Cancer Epidemiol Biomarkers Prev　18：1341-1349，2009

8) Dufresne S, Sauthier P, Mayrand MH, et al : Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with Amplicor HPV and Hybrid Capture 2 assays for detection of high-grade lesions of the uterine cervix. J Clin Microbiol　49：48-53，2011

9) Jacobs MV, de Roda Husman AM, van den Brule AJ, et al : Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol　33：901-905，1995

10) Yoshikawa H, Kawana T, Kitagawa K, et al. Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn J Cancer Res　82：524-531，1991

11) Fujinaga Y, Shimada M, Okazawa K, et al : Simultaneous detection and typing of genital human papillomavirus DNA using the polymerase chain reaction. J Gen Virol　72：1039-1044，1991

12) Bauer, HM, Greer CE, Manos MM : Determination of genital human papillomavirus infection by consensus polymerase chain reaction amplification, In Diagnostic molecular pathology, a practical approach (Herrington CS, McGee JOD eds), IRL Press, Oxford，pp131-152，1993

13) Sasagawa T, Minemoto Y, Basha W, et al : A new PCR-based assay amplifies the E6-E7 genes of most mucosal human papillomaviruses (HPV). Virus Res　67：127-139，2000

14) Sasagawa T, Mitsuishi T : Novel Polymerase Chain Reaction Method for detecting Cutaneous Human Papillomavirus DNA. J Med Virol in press

15) Ermel A, Qadadri B, Morishita A, et al : Human papillomavirus detection and typing in thin prep cervical cytologic specimens comparing the Digene Hybrid Capture II Assay, the Roche Linear Array HPV Genotyping Assay, and the Kurabo GeneSquare Microarray Assay. J Virol Methods　169：154-161，2010

16) Nishiwaki M, Yamamoto T, Tone S, et al : Genotyping of human papillomaviruses by a novel one-step typing method with multiplex PCR and clinical applications. J Clin Microbiol　46：1161-1168，2008

17) 笹川寿之：HPV検査．産婦の実際　58：535-545，2009

18) Day SP, Hudson A, Mast A, et al : Analytical performance of the Investigational Use Only Cervista HPV HR test as determined by a multi-center study. J Clin Virol　45(Suppl1)：S63-S72，2009

19) Muñoz N, Bosch FX, de Sanjosé S, et al : Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med　348：518-527，2003

20) Cuzick J, Clavel C, Petry KU, et al : Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer　119：1095-1101，2006

21) 笹川寿之：子宮頸癌検診におけるHPV-DNA検査の意義．Lab CP　24：69-79，2006

22) Dillner J, Rebolj M, Birembaut P, et al : Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening : joint European cohort study. B M J　337：a1754，2008

23) 笹川寿之，牧野田知：子宮頸がん検診とHPV検査．産と婦　77：1023-1031，2010

24) Wheeler CM, Hunt WC, Schiffman M, et al : Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis　194：1291-1299，2006

25) Khan MJ, Castle PE, Lorincz AT, et al : The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst　97：1072-1079，2005

26) Matsumoto K, Oki A, Furuta R,et al : Predicting the progression of cervical precursor lesions by human papillomavirus genotyping : a prospective cohort study. Int J Cancer　128：2898-2910，2011

27) Kjaer S, Høgdall E, Frederiksen K, et al : The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res　66：10630-10636，2006